HistoSonics

HistoSonics operates at the intersection of interventional oncology, medical devices, and surgical robotics. Its core differentiation is histotripsy: the Edison platform uses focused sound energy and image guidance to mechanically liquefy targeted tissue rather than relying on incisions, needles, thermal ablation, or ionizing radiation. The platform’s positioning is strengthened by its FDA-cleared history, reported use in liver-tumor treatment, and expansion into kidney and pancreatic-tumor clinical applications. HistoSonics is also moving beyond device development into reimbursement and channel creation, illustrated by expanded U.S. insurance coverage, the Gunze Medical agreement in Japan, Cambridge University deployment, Taiwan approval, and the 2026 CE mark. Its $250 million 2025 growth financing and $578.8 million reported cumulative funding indicate substantially greater capitalization than a typical early-stage medical-device developer.

HistoSonics’ trajectory shows a transition from research-derived technology development to regulated commercialization and international expansion. Founded in 2009, the company progressed through venture financing, including $8.3 million in Series B in 2017, a $4.8 million venture round in 2018, two Series C financings totaling approximately $94.7 million in 2019 and 2020, and a $102 million Series D in 2024. The 2022 financing package added an $85 million convertible note and $15 million of debt. A major inflection point came in 2025: Edison gained early market access in Great Britain on May 29, 2025, expanded European clinical visibility through Cambridge University on Jun 10, 2025, and secured a $250 million growth financing on Oct 16, 2025. The company then added Taiwan approval on May 18, 2026, further financing on Jun 22, 2026, and a CE mark on Jul 13, 2026. These events support a trajectory centered on clinical adoption, reimbursement, manufacturing and commercial scale, and geographic expansion.